Human alpha 1-antitrypsin therapy induces fatal anaphylaxis in non-obese diabetic mice

Clinical and Experimental Immunology

Volumn 154, Issue 1, 2008, Pages 15-21

  Lu, Y ^b   Parker, M ^b   Pileggi, A ^c   Zhang, B ^b   Choi, Y K ^b   Molano, R D ^c   Wasserfall, C ^b   Ricordi, C ^c   Inverardi, L ^c   Brantly, M ^b   Schatz, D ^b   Atkinson, M ^b   Song, S ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha 1 antitrypsin; Anaphylaxis; NOD mice; Type 1 diabetes

Indexed keywords

[2 METHOXY 3 (N OCTADECYLCARBAMOYLOXY)PROPYL] (2 THIAZOLIOETHYL) PHOSPHATE; ALBUMIN; ALPHA 1 ANTITRYPSIN; ALPHA 1 ANTITRYPSIN ANTIBODY; ANTIHISTAMINIC AGENT; API; HUMAN ALBUMIN; PROTEIN ANTIBODY; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TRIPROLIDINE; UNCLASSIFIED DRUG; ZEMAIRA;

ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CONTROLLED STUDY; DRUG FATALITY; DRUG SAFETY; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROTEIN PURIFICATION; SUDDEN DEATH;

ALBUMINS; ALPHA 1-ANTITRYPSIN; ANAPHYLAXIS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; SPECIES SPECIFICITY;

EID: 51349135580     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03721.x     Document Type: Article

References (27)

1. Aoki CA, Borchers AT, Ridgway WM, Keen CL, Ansari AA, Gershwin ME. NOD mice and autoimmunity. Autoimmun Rev 2005 4 : 373 9.
2. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005 23 : 447 85.
3. Yoshida K, Kikutani H. Genetic and immunological basis of autoimmune diabetes in the NOD mouse. Rev Immunogenet 2000 2 : 140 6.
4. Shoda LK, Young DL, Ramanujan S et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005 23 : 115 26.
5. Song S, Goudy K, Campbell-Thompson M et al. Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Gene Ther 2004 11 : 181 6.
6. Lu Y, Tang M, Wasserfall C et al. Alpha1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice. Hum Gene Ther 2006 17 : 625 34.
7. Lewis EC, Shapiro L, Bowers OJ, Dinarello CA. Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc Natl Acad Sci USA 2005 102 : 12153 8.
8. Zhang B, Lu Y, Campbell-Thompson M et al. Alpha1-antitrypsin protects beta-cells from apoptosis. Diabetes 2007 56 : 1316 23.
9. Petrache I, Fijalkowska I, Medler TR et al. alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol 2006 169 : 1155 66.
10. Petrache I, Fijalkowska I, Zhen L et al. A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med 2006 173 : 1222 8.
11. Molano RD, Pileggi A, Berney T et al. Prolonged islet allograft survival in diabetic NOD mice by targeting CD45RB and CD154. Diabetes 2003 52 : 957 64.
12. Liu E, Moriyama H, Abiru N et al. Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J Clin Invest 2002 110 : 1021 7.
13. Bernard NF, Ertug F, Margolese H. High incidence of thyroiditis and anti-thyroid autoantibodies in NOD mice. Diabetes 1992 41 : 40 6.
14. Goillot E, Mutin M, Touraine JL. Sialadenitis in nonobese diabetic mice: transfer into syngeneic healthy neonates by splenic T lymphocytes. Clin Immunol Immunopathol 1991 59 : 462 73.
15. Winer S, Astsaturov I, Cheung R et al. Type I diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens; nonimmunized nonobese diabetic mice can develop autoimmune encephalitis. J Immunol 2001 166 : 2831 41.
16. Zhang YC, Powers M, Wasserfall C et al. Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity. Gene Ther 2004 11 : 233 40.
17. Song S, Morgan M, Ellis T et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 1998 95 : 14384 8.
18. Pedotti R, Sanna M, Tsai M et al. Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus. BMC Immunol 2003 4 : 2.
19. Overbergh L, Decallonne B, Branisteanu DD et al. Acute shock induced by antigen vaccination in NOD mice. Diabetes 2003 52 : 335 41.
20. Liu E, Moriyama H, Abiru N et al. Preventing peptide-induced anaphylaxis: addition of C-terminal amino acids to produce a neutral isoelectric point. J Allergy Clin Immunol 2004 114 : 607 13.
21. Staeva-Vieira T, Peakman M, von Herrath M. Translational mini-review series on type 1 diabetes: immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 2007 148 : 17 31.
22. Abusriwil H, Stockley RA. Alpha-1-antitrypsin replacement therapy: current status. Curr Opin Pulm Med 2006 12 : 125 31.
23. Stoller JK, Fallat R, Schluchter MD et al. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events. Chest 2003 123 : 1425 34.
24. Brantly ML, Spencer LT, Humphries M et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006 17 : 1177 86.
25. Flotte TR, Brantly ML, Spencer LT et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 2004 15 : 93 128.
26. Song S, Scott-Jorgensen M, Wang J et al. Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects. Mol Ther 2002 6 : 329 35.
27. Molano RD, Pileggi A, Song S et al. Role of humoral immunity in alpha-1 antitrypsin-induced prolonation of islet allograft survival. Acta Diabetlogica 2007 44 : S33 4.